PO398 A Comparative Analysis of Rheumatic Heart Disease Burden in the Afro versus the Eastern Mediterranean Region

Global Heart ◽  
2018 ◽  
Vol 13 (4) ◽  
pp. 462
Author(s):  
A.M. Abul-Fadl ◽  
A.E. Sarhan ◽  
M. Khallaf ◽  
F. Charl ◽  
S.R. Zaher
2013 ◽  
Vol 43 (4) ◽  
pp. 386-393 ◽  
Author(s):  
M. G. W. Rémond ◽  
K. L. Severin ◽  
Y. Hodder ◽  
J. Martin ◽  
C. Nelson ◽  
...  

2019 ◽  
Vol 7 (10) ◽  
pp. e1388-e1397 ◽  
Author(s):  
Pedro Ordunez ◽  
Ramon Martinez ◽  
Patricia Soliz ◽  
Gloria Giraldo ◽  
Oscar J Mujica ◽  
...  

2016 ◽  
Vol 117 ◽  
pp. S25-S26
Author(s):  
Barış Buğan ◽  
Erkan Yıldırım ◽  
Serdar Fırtına

2020 ◽  
Vol 13 (Supplement_1) ◽  
pp. S28-S32
Author(s):  
Reda M R Ramzy ◽  
Abdul Samid Al Kubati

Abstract Lymphatic filariasis (LF), a neglected tropical disease, is targeted for global elimination as a public health problem. This article reviews the history of LF control and elimination activities in the countries of the World Health Organization's (WHO) Eastern Mediterranean Region (EMR) over the last 2 decades. In 2000, the estimated at-risk population in EMR countries was 12.6 million people, accounting for approximately 1% of the global disease burden. Of the 22 EMR countries, 3 countries (Egypt, Sudan and Yemen) were LF endemic and the disease was suspected in 4 other countries (Djibouti, Oman, Somalia and Saudi Arabia). After almost 2 decades of implementing sustained control and prevention measures, Egypt and Yemen were successfully validated by the WHO as having achieved the elimination criteria in 2017 and 2019, respectively. In 2018, Sudan completed mapping of LF, reaching 26.2% geographical coverage where mass drug administration (MDA) is required and is scaling-up MDA. Extensive epidemiological assessment indicated the absence of LF transmission in the four suspected countries and no MDA required. Challenges faced during the elimination and post-elimination phases are described and discussed.


Sign in / Sign up

Export Citation Format

Share Document